Anti-CD70 antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-11459392-B2
Application number	US-201816224346-A
Country	US
Kind code	B2
Filing date	Dec 18, 2018
Priority date	Jun 19, 2012
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

First claim

What is claimed is:

1. A compound comprising Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI), wherein the compound is an anti-CD70 (αCD70) antibody conjugated to a dolastatin, wherein the conjugation occurs via a non-naturally encoded amino acid in the antibody, wherein Formula (XXXI), (XXXII), (XXXIII), (XXXIV), (XXXV), or (XXXVI) corresponds to:

wherein:
Z has the structure of:

R 5 is H, CO 2 H, C 1 -C 6 alkyl, or thiazole;

R 6 is OH or H;
Ar is phenyl or pyridine;
R 1 is H, an amino protecting group, resin, at least one amino acid, polypeptide or polynucleotide;
R 2 is OH, an ester protecting group, resin, at least one amino acid, polypeptide or polynucleotide;
wherein at least one of R 1 and R 2 is a polypeptide, wherein the polypeptide is an αCD70 antibody, wherein the αCD70 antibody comprises a heavy chain comprising SEQ ID NO: 1, wherein amino acid 119 of SEQ ID NO: 1 is substituted with the non-naturally encoded amino acid;

A is optional, and when present is lower alkylene, substituted lower alkylene, lower cycloalkylene, substituted lower cycloalkylene, lower alkenylene, substituted lower alkenylene, alkynylene, lower heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene or substituted aralkylene;
B is optional, and when present is a linker linked at one end to a diamine containing moiety, wherein the linker selected from the group consisting of lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene, substituted lower heteroalkylene, —O-(alkylene or substituted alkylene)-, —S-(alkylene or substituted alkylene)-, —C(O)R″—, —S(O) k (alkylene or substituted alkylene)-, where k is 1, 2, or 3, —C(O)-(alkylene or substituted alkylene)-, —C(S)-(alkylene or substituted alkylene)-, —NR″-(alkylene or substituted alkylene)-, —CON(R″)-(alkylene or substituted alkylene)-, —CSN(R″)-(alkylene or substituted alkylene)- and —N(R″)CO-(alkylene or substituted alkylene)-, wherein:
each R″ is independently H, alkyl or substituted alkyl;

each of R 3 and R 4 is independently H, halogen, lower alkyl or substituted lower alkyl;
R 7 is C 1 -C 6 alkyl or hydrogen;
each L, L 1 , L 2 , L 3 and L 4 is independently a cleavable or non-cleavable linker selected from the group consisting of a bond, -alkylene-, -alkylene-C(O)—, -alkylene-J-, -(alkylene-O) n -alkylene-, -(alkylene-O) n -alkylene-C(O)—, -(alkylene-O) n -J-, -(alkylene-O) n -J-alkylene-, -(alkylene-O) n —(CH 2 ) n′ —NHC(O)—(CH 2 ) n″ —C(Me) 2 -S—S—(CH 2 ) n′″ —NHC(O)-(alkylene-O) n″″ -alkylene-, -(alkylene-O) n -alkylene-W—, -alkylene-C(O)—W—, -(alkylene-O) n -alkylene-J-, -alkylene′-J-(alkylene-O) n -alkylene-, -(alkylene-O) n -alkylene-J-alkylene′, -J-(alkylene-O) n -alkylene-, -(alkylene-O) n -alkylene-J-(alkylene-O) n ′-alkylene-J′-, —W—, -alkylene-W—, alkylene′-J-(alkylene-NMe) n -alkylene-W—, -J-(alkylene-NMe) n -alkylene-W—, -(alkylene-O) n -alkylene-U-alkylene-C(O)—, -(alkylene-O) n -alkylene-U-alkylene-; -J-alkylene-NMe-alkylene′-NMe-alkylene″-W— and -alkylene-J-alkylene′-NMe-alkylene″-NMe-alkylene′″—W—;
wherein:
each alkylene, alkylene′, alkylene″ and alkylene′″ is independently —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 —;

W has the structure of:

U has the structure of:

each J and J′ independently have the structure of

each n, n′, n″, n′″ and n″″ is independently an integer greater than or equal to one;
D has the structure of:

wherein:
each R 17 is independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, alkylalkoxy, substituted alkylalkoxy, polyalkylene oxide, substituted polyalkylene oxide, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, aralkyl, substituted aralkyl, -(alkylene or substituted alkylene)-ON(R″) 2 , -(alkylene or substituted alkylene)-C(O)SR″, -(alkylene or substituted alkylene)-S—S-(aryl or substituted aryl), —C(O)R″, —C(O) 2 R″ or —C(O)N(R″) 2 ,
wherein each R″ is independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, alkaryl, substituted alkaryl, aralkyl or substituted aralkyl;

each Z 1 is a bond, CR 17 R 17 , O, S, NR′, CR 17 R 17 —CR 17 R 17 , CR 17 R 17 —O, O—CR 17 R 17 , CR 17 R 17 —S, S—CR 17 R 17 , CR 17 R 17 —NR′ or NR′—CR 17 R 17 ;
wherein each R′ is H, alkyl or substituted alkyl;

each Z 2 is selected from the group consisting of a bond, —C(O)—, —C(S)—, optionally substituted C 1 -C 3 alkylene, optionally substituted C 1 -C 3 alkenylene and optionally substituted heteroalkyl;
each Z 3 is independently selected from the group consisting of a bond, optionally substituted C 1 -C 4 alkylene, optionally substituted C 1 -C 4 alkenylene, optionally substituted heteroalkyl, —O—, —S—, —C(O)—, —C(S)— and —N(R′)—;
each T 3 is a bond, C(R″)(R″), O or S; with the proviso that when T 3 is O or S, R″ cannot be halogen; wherein each R″ is H, halogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
M 2 is:

 wherein (a) indicates bonding to the B group and (b) indicates bonding to respective positions within the heterocycle group;
M 3 is:

 where (a) indicates bonding to the B group and (b) indicates bonding to respective positions within the heterocycle group;
M 4 is:

 wherein (a) indicates bonding to the B group and (b) indicates bonding to respective positions within the heterocycle group;
each R 19 is independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, ester, ether, thioether, aminoalkyl, halogen, alkyl ester, aryl ester, amide, aryl amide, alkyl halide, alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester, halosulfonyl, nitrile, alkyl nitrile and nitro; and
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.

2. The compound of claim 1 , comprising Formula (XXXI-A):

Assignees

• Ambrx Inc

Inventors

• Barnett Richard S
• Knudsen Nick
• Sun Ying
• Biroc Sandra
• Buss Timothy
• Javahishvili Tsotne
• Bresson Damien
• Srinagesh Shailaja
• Hewet Amha
• Pinkstaff Jason

Classifications

• A61K47/6845

  the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K47/6889

  Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title